Moleculin Biotech, Inc. · NASDAQ:MBRX
Moleculin Biotech — Investor Presentation (January 2021)
31 slides from Moleculin Biotech's investor presentation, Jan 11, 2021
Slide 1: Moleculin Biotech Public Presentation
<> Moleculin’ : Developing ground-breaking therapies . if for highly resistant cancers and viruses January 10, 2021 Public Presentation (Nasdaq: MBRX)
Slide 2: Disclaimer
Disclaimer All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words “believe,”
Slide 3: Introduction by the Numbers
Slide 4: Moleculin Biotech, Inc. Core Technologies
oleculin Biotech, In 3 Core Technologies * Annamycin —“ Next generation” noncardiotoxic anthracycline * WP1066/WP1220 —first-in-class p-STAT3 inhibitors * WP1122 —antimetabolites targeting glycolysis and glycosylation * Provides for “multiple shots on goal” =~ ®Moleculin
Slide 5: Moleculin Biotech, Inc. Clinical Trials - 2020
oleculin Biotech, In 5 Clinical Trials - 2020 interval * US P1in AML completed Baek * EU P1/2 AML under way * EU P1 PoC in Cutaneous T-Cell Lymphoma (CTCL) completed Externally * US P1in GBM under way Funded * US P1in Pediatric brain tumors under way (including DIPG) =~ ®Moleculin
Slide 6: Moleculin Biotech, Inc. Drugs with Human Activity
Moleculin Biotech, Inc. q . EI Drugs with Human Activity All at * Annamycin in AML MUielieelastiiel © \VP1066 in DIPG SCE WP1220 in CTCL = ® Moleculin
Slide 7: Moleculin Biotech, Inc. Clinical Trials - 2021
oleculin Biotech, In Ey Clinical Trials - 2021 Projected trials in 2021 interialt * EU P1/2—AML (Annamycin single agent) Baek * EU P1/2—AML (Annamycin + Ara-C) * US P1/2 — Sarcoma lung mets (Annamycin) * EU P1/2—Sarcoma lung mets (Annamycin) Externally + US P1—GBM (WP1066; expanding to combination w
Slide 8: Multiple Shots on Goal
oleculin Biotech, Inc. aE Multiple Shots on Goal * Reduces risk associated with single-technology companies * Provides investors more than one way to benefit * Spreads fixed costs across multiple development platforms =~ ®Moleculin
Slide 9: Moleculin Biotech, Inc. Employees
=~ ®Moleculin oleculin Biotech, In 415 Employees * Extensive drug development and life science experience * Supported by over 150 contractors worldwide * Industry-leading advisory board * Public in 2016 * Technology licensed from MD Anderson Cancer Center
Slide 10: Q3 2021 Cash Runway
oleculin Biotech, Inc. /Q3 2021 Cash Runway =~ ®Moleculin Estimated by management with projected trials to end of Q3-2021 Approx. 69 million shares outstanding Approx. $22 million raised in 2020 Target minimum of 9 mos cash runway on-hand Opco ATM and Lincoln Park Equity Line available Continued eff
Slide 11: Corporate Presentation
Slide 12: Executive Management Team
=~ ~@) Moleculin Walter Klemp, Chairman, President & CEO Don Picker, PhD Chief Science Officer Jonathan P. Foster, CPA, CCMA EVP & CFO Robert Shepard, MD, FACP Chief Medical Officer Sandra Silberman, MD & PhD Chief Medical Officer - New Products tive Manag t Team ; Selected Prior Experience soliton
Slide 13: Science Advisory Board
Science Advisory Board Waldemar Priebe, PhD ree unvensrv or reas MDAnderson Geaneer Center Paul 4 Waymack, Pancreatic James Abbruzese, MD DANA-FARBER CANCER INSTITOTE uv Duke University School of Medicine Hematology Elihu Estey, A MD FRED HUTCH Jonns Horan Marty Tallman, MD Memorial Sloan Kettering.
Slide 14: Three Core Technologies
Three Core Technologies Immune / Transcription Modulators * p-STAT3 inhibitor + Key cancer and viral signaling pathway + fimmune response/memory WP1066/WP1220 ®S Moleculin Antimetabolites / Glycosylation Inhibitor
Slide 15: Multiple Candidates/Multiple Indications
Multiple Candidates/Multiple Indication Drug In Vitro Animal IND/ Human Candidate Indication Activity Activity In Clinic Activity Annamycin WP1066 WP1220 WP1122 Pancreatic WP1096/ WP1097 *2.DG (active moiety in WP1122) active in Phase 2 COVID-19 trial conducted S Moleculin by an unrelated company in
Slide 16: Leading Partnerships, Collaborations
Leading Partnerships, Collaborations Our world-leading partnerships & collaborations significantly expand our research capabilities and increase our knowledgebase REGA INSTITUTE KU LEUVEN Dr. Dominique Schols of the Rega Institute has joined the Moleculin Science Advisory Board ‘Annamycin AML trial
Slide 17: Transcription Modulators
Transcription Modulators Inhibit pSTA DS Moleculin , HIF-Los, c-Myc | Act | Expected Targeting major cancer center in US Existing brain tumor collaborators wed Pharima Is Q) ovwrensisy or exces 3 major university virology centers 7
Slide 18: Development Pipeline — Externally Funded
Development Pipeline — Externally Funde In Clinic coma Met Sponsored trial at MD Anderson Cancer Center ‘ MAYO CLINIC Modul m ) (a BMORY Inhibit pSTATS, HIF-10, c md Actively seeking collaborative partner wep 's: Pharunacculicals Expected
Slide 19: WP1122 and COVID-19
S Moleculin 2-DG (active moiety of WP1122) shown active in COVID-19 patients in India* WP11 jown more activ against SARS-CoV-2 than 2- DG in vitro Preclinical toxicology for IND completed Awaiting suitable COVID-19 animal model (1H21)
Slide 20: COVID-19 Roadmap
COVID-19 Roadmap QJ Molecutin * Based on public disclosures of trial conducted by an unrelated company in india ** FDArequites validation in a COVID-19 animal model; previously contracted and announced hamster model has been deemed unsuitable for WP1122 and the Company is now attempting to contract
Slide 21: Potential 2021/2022 Value Inflection Points
Potential 2021/2022 Value Inflection Points 2H 4H | 2H AML Single Agent P1/2 @ AML Combination with Ara-C P1/2 e USSTS P21 EUSTS GBM Single Agent P1/2 | GBM Combination with radiation P1/2 ¢ DIPG P1 | DIPG P2 Pivotal A CTCL 2 Oa | COVID-19 P1a/1b COVID-19 P2 Pivotal e ile/Award @® Milestone [Start W
Slide 22: Financial Review
Slide 23: Financial Summary
In thousands, except for share and per share data and shares outstanding For the Year Ended 12/31/19 9/30/2020 (Unaudited) Revenue General and administrative and depreciation Net loss Basic and diluted weighted average shares outstanding Cash and cash equivalents Total current assets Total current l
Slide 24: Various Sources of Financing
Various Sources of Financi Opportunistic Approach Approx. $20 million raised 2019; Approx. $22 million in 2020 Three analysts cover MBRX — Roth, Maxim, & Opco Overnight deals $15 million ATM — Opco Equity Line - $22 million Lincoln Park Capital Successful out-licensing of technology in low priority
Slide 25: Appendix
Slide 26: AML Landscape
n - AML Landscap ; AML Patients No Viable Options 38% 60% Fit for intensive Chemo = ® Moleculin Approximately 160,000 incident cases worldwide 40% are unfit for intensive chemotherapy About 15% (25% of fit patients) treated with SOC will remiss or move on to BMT About 2% and 1% are helped by agents
Slide 27: STS Lung Mets Landscape
TS Lung Mets Landscape Soft Tissue Sarcoma * Approximately 130,000 incident cases 20% to 50% worldwide may * 20% to 50% will have lung mets benefit * About 30% will have success with from - resection (PM = Pulmonary Annaimyeln Metastasectomy) * Most treated with doxorubicin, with or No Lung without
Slide 28: WP1066 and DIPG
WP1 dsca * Significant unmet need remains in Diffuse Interstitial Pontine Glioma (DIPG) * 10% of all childhood CNS tumors - 200-400 estimated annual incidence of DIPG * Arise in the brainstem, which controls vital functions, thus unable to be surgically removed * Treatment is radiation therapy, whic
Slide 29: WP1220 - CTCL Landscape
WP1220 - CTCL Landscape US & EU 48% * Incidence ~ 16,000 worldwide in 2020 (US + EU 48%) growing to 18,000 by 2026 * Asia has the highest incidence (38%) * Stage I-Il represents approximately 73%-80% of cases * Prevalence is 42,000 in US & EU growing to 45,000 with prevalence in Japan — 49,000 by Eu
Slide 30: COVID-19 Treatment Landscape
Classification = BZ Motecutin Sve sore nan hfs ov 6,20 461 treatment (therapeutic) projects are being tracked More than 50% of them are Preclinical Advancing WP1122 to Phase 1 will put us in rare company We are only 1 of 2 known to be pursuing glycolysis, with the other being Dr. Reddy’s with 2-DG W
Slide 31: Investment Highlights
Investment Highlights 3 Potential Blockbuster Technologies < loxic anthracycline 5 2020 Phase 4 clinical trials 3 Drugs showing early human activity 8 2021 Phase 1 & 2 trials expected Y World class collaboration Highly experienced team Exclusive IP/Fast Track Potential SMolecutin A
Moleculin Biotech — Investor Presentation (January 2021) on 6ix